Frederick, Dennie T.

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science

Single-cell and spatial transcriptomicsCancer Immunotherapy and Biomarkers

Cited by 4,944

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 2,053

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science

Pancreatic and Hepatic Oncology ResearchBacterial Cancer Therapy

Cited by 1,817

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature

Melanoma and MAPK PathwaysCancer Cells and Metastasis

Cited by 1,771

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,429

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,005

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma

Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 944

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., Frederick, D. T., Hurley, A. D., Nellore, A., Kung, A. L., et al. (2013) · Cancer Cell

Melanoma and MAPK PathwaysCancer, Hypoxia, and Metabolism

Cited by 818

Toward Minimal Residual Disease-Directed Therapy in Melanoma

Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell

Melanoma and MAPK PathwaysCancer Cells and Metastasis

Cited by 771

Intratumoral activity of the cxcr3 chemokine system is required for the efficacy of anti-PD-1 therapy

Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019) · Immunity

Cancer Immunotherapy and BiomarkersChemokine receptors and signaling

Cited by 716

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics

Hippo pathway signaling and YAP/TAZMelanoma and MAPK Pathways

Cited by 551

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 481

MAP Kinase Pathway Alterations in BRAF -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 478

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., et al. (2013) · Nature

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 452

RETRACTED ARTICLE: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., et al. (2016) · Nature

Melanoma and MAPK PathwaysWnt/β-catenin signaling in development and cancer

Cited by 398

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2019) · Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 344

Elucidating Distinct Roles for NF1 in Melanomagenesis

Maertens, O., Johnson, B., Hollstein, P., Frederick, D. T., Cooper, Z. A., Messiaen, L., Bronson, R. T., McMahon, M., Granter, S., Flaherty, K., et al. (2013) · Cancer Discovery

Melanoma and MAPK PathwaysNeurofibromatosis and Schwannoma Cases

Cited by 258

In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer

Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., et al. (2022) · Nature Immunology

Cancer Immunotherapy and BiomarkersImmune Cell Function and Interaction

Cited by 218

Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice

Li, Y., Tinoco, R., Elmén, L., Segota, I., Xian, Y., Fujita, Y., Sahu, A., Zarecki, R., Marie, K., Feng, Y., et al. (2019) · Nature Communications

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 212

Targeting TBK1 to overcome resistance to cancer immunotherapy

Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., et al. (2023) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 174

Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

Somasundaram, R., Zhang, G., Fukunaga-Kalabis, M., Perego, M., Krepler, C., Xu, X., Wagner, C., Hristova, D., Zhang, J., Tian, T., et al. (2017) · Nature Communications

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 151

A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF -mutated Melanoma to MAPK Inhibitors

Aloia, A., Müllhaupt, D., Chabbert, C. D., Eberhart, T., Flückiger-Mangual, S., Vukolic, A., Eichhoff, O., Irmisch, A., Alexander, L. T., Scibona, E., et al. (2019) · Clinical Cancer Research

Melanoma and MAPK PathwaysCancer, Lipids, and Metabolism

Cited by 130

Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses

Lo, J. A., Kawakubo, M., Juneja, V. R., Su, M. Y., Erlich, T. H., LaFleur, M. W., Kemeny, L. V., Rashid, M., Malehmir, M., Rabi, S. A., et al. (2021) · Science Translational Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 97